HETLIOZ

Drug Vanda Pharmaceuticals Inc.
Total Payments
$3.5M
Transactions
84,949
Doctors
18,161
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2024 $420,575 15,704 5,794
2023 $607,263 16,389 5,770
2022 $1.6M 24,330 7,774
2021 $662,507 19,941 6,743
2020 $294,475 8,585 3,326

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $1.8M 84,785 50.1%
Unspecified $1.7M 155 46.8%
Charitable Contribution $60,000 3 1.7%
Consulting Fee $52,184 3 1.5%
Education $36.52 2 0.0%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30.83 1 0.0%

Payments by Type

General
$1.9M
84,794 transactions
Research
$1.7M
155 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) Vanda Pharmaceuticals Inc. $757,327 1
AN OPEN-LABEL, TWO-PERIOD, RANDOMIZED, SINGLE ORAL DOSE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF 20 MG TASIMELTEON CAPSULE FORMULATION RELATIVE TO 5 ML TASIMELTEON LIQUID SUSPENSION FORMULATION IN HEALTHY VOLUNTEERS Vanda Pharmaceuticals Inc. $596,202 0
EVALUATING THE EFFECTS OF TASIMELTEON VS PLACEBO ON SLEEP DISTURBANCES IN SMS Vanda Pharmaceuticals Inc. $231,664 1
EVALUATING THE EFFECTS OF TASIMELTEON IN INDIVIDUALS WITH AUTISM SPECTRUM DISORDER (ASD) AND SLEEP DISTURBANCES Vanda Pharmaceuticals Inc. $44,167 0
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TASIMELTEON IN TREATING SLEEP DISTURBANCES IN INDIVIDUALS WITH AUTISM SPECTRUM DISORDER Vanda Pharmaceuticals Inc. $21,025 0
EVALUATING THE EFFECTS OF TASIMELTEONIN INDIVIDUALS WITH AUTISM SPECTRUM DISORDER (ASD) AND SLEEP DISTURBANCES Vanda Pharmaceuticals Inc. $9,350 0

Top Doctors Receiving Payments for HETLIOZ — Page 5

Doctor Specialty Location Total Records
, MD Psychiatry Elgin, IL $919.60 45
, PA-C Physician Assistant Rosemead, CA $919.54 38
, APRN, FNP Family Oklahoma City, OK $916.85 35
, M.D Psychiatry Wichita, KS $913.38 42
, M.D Psychiatry Worcester, MA $910.06 34
, PSYCHIATRY MD Psychiatry Tuscaloosa, AL $908.01 40
, PMHNP Psychiatric/Mental Health Cleveland, MS $907.05 58
, DNP, AAPRN, PMHNP Psychiatric/Mental Health Tarpon Springs, FL $903.85 38
, M.D Psychiatry Agoura Hills, CA $897.09 45
, PA-C Medical Costa Mesa, CA $893.05 33
, MD Psychiatry Fairfield, CT $884.42 50
, MD Internal Medicine Noblesville, IN $880.83 43
, M.D Internal Medicine Saint Joseph, MO $879.44 36
Kiefer Greenspan Psychiatry Chicago, IL $878.44 33
, M.D Psychiatry Aventura, FL $877.80 39
, FNP Family Jacksonville, NC $874.64 58
, CNS Registered Nurse Providence, RI $872.81 35
, APRN Psychiatric/Mental Health Houma, LA $872.12 35
, PMHNP-BC Registered Nurse Fort Myers, FL $866.18 38
, M.D Internal Medicine Louisville, KY $865.11 42
, M.D, PH.D Psychiatry Gaithersburg, MD $862.06 40
, D.O Hospice and Palliative Medicine Indianapolis, IN $861.59 36
, PMHNP Psychiatric/Mental Health Jacksonville, FL $861.54 34
, M.D Psychiatry Chicago, IL $859.58 37
, M.D Psychiatry Mount Vernon, MO $857.81 52

About HETLIOZ

HETLIOZ is a drug associated with $3.5M in payments to 18,161 healthcare providers, recorded across 84,949 transactions in the CMS Open Payments database. The primary manufacturer is Vanda Pharmaceuticals Inc..

Payment data is available from 2020 to 2024. In 2024, $420,575 was paid across 15,704 transactions to 5,794 doctors.

The most common payment nature for HETLIOZ is "Food and Beverage" ($1.8M, 50.1% of total).

HETLIOZ is associated with 6 research studies, including "EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD)" ($757,327).